



FOR IMMEDIATE RELEASE

## Manufacturing has begun for Cancer Advances' Lead Product

**Durham, NC, May 5, 2016**— [Cancer Advances Inc.](#), a wholly owned subsidiary of Cato Holding Company, is excited to announce that drug manufacturing efforts for their lead product are underway.

Manufacturing activities have been initiated for Cancer Advances' lead product G17DT Immunogen. This work has been contracted with Nova Laboratories (Leicester, UK) and production of initial GMP batches are planned for this summer. It is anticipated that production of the drug substance and subsequent manufacture of drug product will be completed in a 3-6 month timeframe.

Cancer Advances is excited that the manufacturing activities have been initiated and look forward to the availability of clinical trial materials for on-going studies in the near future.

### **About Cancer Advances Inc.**

Cancer Advances Inc., a wholly owned subsidiary of Cato Holding Company, is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.

**Please visit our product page for more information on what is in development:** <http://www.canceradvancesinc.com/product.html>

Contact: Lynda Sutton

President [Cancer Advances, Inc.](#)

Phone: 919-361-2162 Email: [info@canceradvancesinc.com](mailto:info@canceradvancesinc.com)

Cancer  
Advances is  
DEDICATED  
to enhancing  
the immune system  
and augmenting  
human quality of life by  
targeting the progression  
of gastrointestinal cancers.

Cancer Advances

P | 919-361-2162

E | [info@canceradvancesinc.com](mailto:info@canceradvancesinc.com)

[www.canceradvancesinc.com](http://www.canceradvancesinc.com)